B-Lymphoid Blast Phase-Chronic Myeloid Leukemia: Current Therapeutics

Area of Science:

• Hematology
• Oncology
• Leukemia Research

Background:

• Blast crisis (BC) is a critical complication of chronic myeloid leukemia (CML).
• The advent of BCR-ABL tyrosine kinase inhibitors (TKIs) has reduced BC incidence.
• Despite TKI therapy, outcomes for CML BC remain challenging, highlighting an unmet need for novel treatments.

Purpose of the Study:

• To provide a comprehensive review of the current management strategies for lymphoid BC.
• To summarize the therapeutic objectives and outcomes in the TKI era for CML BC.

Main Methods:

• Literature review of current management of lymphoid BC.
• Analysis of treatment objectives, including achieving a second chronic phase (CP) and suitability for allogeneic stem cell transplantation (SCT).

Main Results:

• BC incidence has decreased with TKI use.
• Achieving a second CP and proceeding to SCT are primary treatment goals.
• Current TKIs provide limited long-term remissions in BC.

Conclusions:

• Lymphoid BC management requires further advancement.
• There is a significant unmet need for innovative therapeutic approaches for CML BC.
• Current strategies focus on achieving CP and SCT, but novel therapies are essential for improved patient outcomes.